Immunome (IMNM) Stock Price, News & Analysis

Company Overview

Immunome, Inc., a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.

Key Stats

• Today's Range: $8.75 to $9.16
• 50-Day Range: $8.73 to $11.83
• 52-Week Range: $8.39 to $26.70
• Volume: 453,030 shs
• Average Volume: 896,133 shs
• Market Capitalization: $699.64 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $27.17
• Consensus Rating: Buy

Immunome Stock Analysis - MarketRank™

Immunome scored higher than 39% of companies evaluated by MarketBeat, and ranked 734th out of 932 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Immunome has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Immunome has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Immunome are expected to decrease in the coming year, from ($2.21) to ($3.23) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Immunome is -1.08, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Immunome is -1.08, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Immunome has a P/B Ratio of 3.17. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

13.35% of the float of Immunome has been sold short.

Short Interest Ratio / Days to Cover

Immunome has a short interest ratio ("days to cover") of 10.3, which indicates bearish sentiment.

Change versus previous month

Short interest in Immunome has recently decreased by 0.53%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Immunome does not currently pay a dividend.

Dividend Growth

Immunome does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

13.35% of the float of Immunome has been sold short.

Short Interest Ratio / Days to Cover

Immunome has a short interest ratio ("days to cover") of 10.3, which indicates bearish sentiment.

Change versus previous month

Short interest in Immunome has recently decreased by 0.53%, indicating that investor sentiment is improving.

News and Social Media

• Score: 2.5 / 5
• News Sentiment: 0.45

News Sentiment

Immunome has a news sentiment score of 0.45. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.73 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 17 news articles for Immunome this week, compared to 4 articles on an average week.

MarketBeat Follows

12 people have added Immunome to their MarketBeat watchlist in the last 30 days. This is an increase of 20% compared to the previous 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: Acquiring Shares

Insider Buying vs. Insider Selling

In the past three months, Immunome insiders have bought more of their company's stock than they have sold. Specifically, they have bought $1,162,500.00 in company stock and sold $0.00 in company stock.

Percentage Held by Insiders

Only 8.60% of the stock of Immunome is held by insiders.

Percentage Held by Institutions

44.58% of the stock of Immunome is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

IMNM Stock Analysis - Frequently Asked Questions

How have IMNM shares performed this year?

Immunome's stock was trading at $10.62 at the beginning of the year. Since then, IMNM stock has decreased by 17.4% and is now trading at $8.77.
View the best growth stocks for 2025 here.

How were Immunome's earnings last quarter?

Immunome, Inc. (NASDAQ:IMNM) announced its earnings results on Monday, November, 15th. The company reported ($0.65) earnings per share for the quarter, missing analysts' consensus estimates of ($0.51) by $0.14. Immunome had a negative trailing twelve-month return on equity of 48.63% and a negative net margin of 3,014.59%.

When did Immunome IPO?

Immunome (IMNM) raised $30 million in an initial public offering on Friday, October 2nd 2020. The company issued 2,500,000 shares at $11.00-$13.00 per share. Ladenburg Thalmann and Chardan served as the underwriters for the IPO.

Who are Immunome's major shareholders?

Immunome's top institutional shareholders include T. Rowe Price Investment Management Inc. (6.89%), Redmile Group LLC (6.05%), Enavate Sciences GP LLC (4.36%) and Janus Henderson Group PLC (4.33%). Insiders that own company stock include Max Rosett, Bruce Turner, Philip Tsai, Jack Higgins and Robert Lechleider.
View institutional ownership trends.

How do I buy shares of Immunome?

Shares of IMNM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Immunome own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Immunome investors own include NVIDIA (NVDA), Humana (HUM), Broadcom (AVGO), Meta Platforms (META), Arista Networks (ANET), Adobe (ADBE) and e.l.f. Beauty (ELF).

Company Calendar

• Last Earnings: 11/15/2021
• Today: 3/14/2025
• Next Earnings (Estimated): 3/27/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:IMNM
• CIK: 1472012
• Web: immunome.com
• Phone: 610-321-3700
• Fax: N/A
• Employees: 40
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $27.17
• High Stock Price Target: $35.00
• Low Stock Price Target: $20.00
• Potential Upside/Downside: +209.8%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 6 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($8.11)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-106,810,000.00
• Net Margins: -3,014.59%
• Pretax Margin: -3,014.59%
• Return on Equity: -48.63%
• Return on Assets: -41.62%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 6.17
• Quick Ratio: 6.17

Sales & Book Value

• Annual Sales: $10.13 million
• Price / Sales: 69.07
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.77 per share
• Price / Book: 3.17

Miscellaneous

• Outstanding Shares: 79,777,000
• Free Float: 72,916,000
• Market Cap: $699.64 million
• Optionable: Optionable
• Beta: 1.93